232 related articles for article (PubMed ID: 33246428)
1. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.
Salazar R; Capdevila J; Manzano JL; Pericay C; Martínez-Villacampa M; López C; Losa F; Safont MJ; Gómez-España A; Alonso-Orduña V; Escudero P; Gallego J; García-Paredes B; Palacios A; Biondo S; Grávalos C; Aranda E;
BMC Cancer; 2020 Nov; 20(1):1164. PubMed ID: 33246428
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Borg C; Mantion G; Boudghène F; Mornex F; Ghiringhelli F; Adenis A; Azria D; Balosso J; Ben Abdelghani M; Bachet JB; Vendrely V; François Y; Conroy T; Rio E; Roullet B; Spaëth D; Quero L; Lakkis Z; Coudert M; Ionescu-Goga M; Tanang A; André T
Clin Colorectal Cancer; 2019 Sep; 18(3):200-208.e1. PubMed ID: 31311761
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
4. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
5. Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial.
Velenik V; Zadnik V; Omejc M; Grosek J; Tuta M
Radiol Oncol; 2020 Aug; 54(4):461-469. PubMed ID: 32738130
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
Velenik V; Ocvirk J; Music M; Bracko M; Anderluh F; Oblak I; Edhemovic I; Brecelj E; Kropivnik M; Omejc M
Radiat Oncol; 2011 Aug; 6():105. PubMed ID: 21880132
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
Salazar R; Capdevila J; Laquente B; Manzano JL; Pericay C; Villacampa MM; López C; Losa F; Safont MJ; Gómez A; Alonso V; Escudero P; Gallego J; Sastre J; Grávalos C; Biondo S; Palacios A; Aranda E
BMC Cancer; 2015 Feb; 15():60. PubMed ID: 25886378
[TBL] [Abstract][Full Text] [Related]
8. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C;
Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.
García M; Martinez-Villacampa M; Santos C; Navarro V; Teule A; Losa F; Pisa A; Cambray M; Soler G; Lema L; Kreisler E; Figueras A; Juan XS; Viñals F; Biondo S; Salazar R
BMC Cancer; 2015 Feb; 15():59. PubMed ID: 25886275
[TBL] [Abstract][Full Text] [Related]
10. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J
Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Radiotherapy with Capecitabine Plus Bevacizumab for Locally Advanced Lower Rectal Cancer: Results of a Single-institute Phase II Study.
Maeda K; Shibutani M; Otani H; Fukuoka T; Iseki Y; Matsutani S; Nagahara H; Inoue T; Tachimori A; Nishii T; Miki Y; Hosono M; Ohira M
Anticancer Res; 2018 Jul; 38(7):4193-4197. PubMed ID: 29970549
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K
J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Preoperative Chemoradiotherapy and Combined Chemotherapy with Radiotherapy Without Surgery for Locally Advanced Rectal Cancer.
Supaadirek C; Pesee M; Thamronganantasakul K; Thalangsri P; Krusun S; Supakalin N
Asian Pac J Cancer Prev; 2016; 17(7):3511-4. PubMed ID: 27510001
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.
Cho H; Kim JE; Kim KP; Yu CS; Kim JC; Kim JH; Lee MA; Jang HS; Oh ST; Kim SY; Oh JH; Kim DY; Hong YS; Kim TW
Am J Clin Oncol; 2016 Dec; 39(6):623-629. PubMed ID: 27322695
[TBL] [Abstract][Full Text] [Related]
15. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
16. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
Park JH; Yoon SM; Yu CS; Kim JH; Kim TW; Kim JC
Cancer; 2011 Aug; 117(16):3703-12. PubMed ID: 21328328
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
20. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
